StockNews.com Lowers Collegium Pharmaceutical (NASDAQ:COLL) to Buy

StockNews.com downgraded shares of Collegium Pharmaceutical (NASDAQ:COLL) from a strong-buy rating to a buy rating in a research note issued to investors on Wednesday.

Several other research analysts have also issued reports on COLL. HC Wainwright upped their target price on Collegium Pharmaceutical from $47.00 to $50.00 and gave the company a “buy” rating in a research report on Thursday, September 5th. Piper Sandler reaffirmed a “neutral” rating and issued a $37.00 price objective on shares of Collegium Pharmaceutical in a research report on Friday, October 11th. Needham & Company LLC reissued a “hold” rating on shares of Collegium Pharmaceutical in a research report on Friday, August 9th. Finally, Truist Financial upped their price target on shares of Collegium Pharmaceutical from $40.00 to $42.00 and gave the company a “buy” rating in a research note on Friday, August 9th. Two investment analysts have rated the stock with a hold rating and four have assigned a buy rating to the stock. Based on data from MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and a consensus target price of $42.60.

Collegium Pharmaceutical Stock Up 1.1 %

Shares of Collegium Pharmaceutical stock opened at $34.70 on Wednesday. The company has a quick ratio of 1.04, a current ratio of 1.11 and a debt-to-equity ratio of 1.71. The company has a market cap of $1.14 billion, a P/E ratio of 14.46 and a beta of 0.94. The firm’s 50 day moving average price is $37.66 and its 200-day moving average price is $35.35. Collegium Pharmaceutical has a 52-week low of $20.95 and a 52-week high of $42.29.

Collegium Pharmaceutical (NASDAQ:COLL) last announced its earnings results on Thursday, August 8th. The specialty pharmaceutical company reported $1.62 earnings per share for the quarter, beating the consensus estimate of $1.40 by $0.22. The company had revenue of $145.28 million during the quarter, compared to the consensus estimate of $143.94 million. Collegium Pharmaceutical had a net margin of 17.32% and a return on equity of 107.62%. Collegium Pharmaceutical’s revenue was up 7.2% compared to the same quarter last year. During the same period last year, the firm earned $1.13 earnings per share. On average, sell-side analysts predict that Collegium Pharmaceutical will post 5.79 EPS for the current fiscal year.

Insider Buying and Selling

In related news, EVP Thomas B. Smith sold 9,593 shares of the stock in a transaction that occurred on Friday, September 13th. The shares were sold at an average price of $36.62, for a total value of $351,295.66. Following the transaction, the executive vice president now owns 53,816 shares in the company, valued at approximately $1,970,741.92. This represents a 0.00 % decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. In other Collegium Pharmaceutical news, EVP Shirley R. Kuhlmann sold 19,248 shares of Collegium Pharmaceutical stock in a transaction dated Thursday, September 5th. The stock was sold at an average price of $38.30, for a total transaction of $737,198.40. Following the completion of the transaction, the executive vice president now owns 120,161 shares in the company, valued at approximately $4,602,166.30. This trade represents a 0.00 % decrease in their position. The transaction was disclosed in a filing with the SEC, which is accessible through this link. Also, EVP Thomas B. Smith sold 9,593 shares of the business’s stock in a transaction dated Friday, September 13th. The shares were sold at an average price of $36.62, for a total value of $351,295.66. Following the completion of the transaction, the executive vice president now directly owns 53,816 shares of the company’s stock, valued at approximately $1,970,741.92. This trade represents a 0.00 % decrease in their position. The disclosure for this sale can be found here. Corporate insiders own 3.98% of the company’s stock.

Institutional Trading of Collegium Pharmaceutical

Hedge funds and other institutional investors have recently bought and sold shares of the stock. Pacer Advisors Inc. lifted its holdings in Collegium Pharmaceutical by 31.8% in the second quarter. Pacer Advisors Inc. now owns 3,408,369 shares of the specialty pharmaceutical company’s stock valued at $109,749,000 after acquiring an additional 821,541 shares during the period. Rubric Capital Management LP lifted its stake in shares of Collegium Pharmaceutical by 27.2% in the 2nd quarter. Rubric Capital Management LP now owns 2,333,500 shares of the specialty pharmaceutical company’s stock valued at $75,139,000 after purchasing an additional 499,473 shares during the period. Assenagon Asset Management S.A. boosted its holdings in Collegium Pharmaceutical by 411.1% during the second quarter. Assenagon Asset Management S.A. now owns 362,137 shares of the specialty pharmaceutical company’s stock worth $11,661,000 after buying an additional 291,286 shares in the last quarter. LSV Asset Management boosted its holdings in Collegium Pharmaceutical by 188.7% during the first quarter. LSV Asset Management now owns 380,551 shares of the specialty pharmaceutical company’s stock worth $14,773,000 after buying an additional 248,751 shares in the last quarter. Finally, Principal Financial Group Inc. grew its position in Collegium Pharmaceutical by 8.2% during the second quarter. Principal Financial Group Inc. now owns 1,680,860 shares of the specialty pharmaceutical company’s stock valued at $54,124,000 after buying an additional 128,003 shares during the period.

About Collegium Pharmaceutical

Collegium Pharmaceutical, Inc, a specialty pharmaceutical company, engages in the development and commercialization of medicines for pain management. Its portfolio includes Xtampza ER, an abuse-deterrent, extended-release, and oral formulation of oxycodone for the management of pain severe enough to require daily, around-the-clock, long-term opioid treatment; Nucynta ER and Nucynta IR, which are extended-release and immediate-release formulations of tapentadol, indicated for the management of acute, severe, and persistent pain; Belbuca, a buccal film that contains buprenorphine; and Symproic, an oral formulation of naldemedine for the treatment of opioid-induced constipation in adult patients with chronic non-cancer pain.